Search

Your search keyword '"Hvas, Christian Lodberg"' showing total 348 results
Start Over Author "Hvas, Christian Lodberg"
348 results on '"Hvas, Christian Lodberg"'

1. International consensus statement on microbiome testing in clinical practice

Author

Porcari, Serena, Mullish, Benjamin H, Asnicar, Francesco, Ng, Siew C, Zhao, Liping, Hansen, Richard, O'Toole, Paul W, Raes, Jeroen, Hold, Georgina, Putignani, Lorenza, Hvas, Christian Lodberg, Zeller, Georg, Koren, Omry, Tun, Hein, Valles-Colomer, Mireia, Collado, Maria Carmen, Fischer, Monika, Allegretti, Jessica, Iqbal, Tariq, Chassaing, Benoit, Keller, Josbert, Baunwall, Simon Mark, Abreu, Maria, Barbara, Giovanni, Zhang, Faming, Ponziani, Francesca Romana, Costello, Sam P, Paramsothy, Sudarshan, Kao, Dina, Kelly, Colleen, Kupcinskas, Juozas, Youngster, Ilan, Franceschi, Francesco, Khanna, Sahil, Vehreschild, Maria, Link, Alexander, De Maio, Flavio, Pasolli, Edoardo, Miguez, Aitor Blanco, Brigidi, Patrizia, Posteraro, Brunella, Scaldaferri, Franco, Stojanovic, Mirjana Rajilic, Megraud, Francis, Malfertheiner, Peter, Masucci, Luca, Arumugam, Manimozhiyan, Kaakoush, Nadeem, Segal, Eran, Bajaj, Jasmohan, Leong, Rupert, Cryan, John, Weersma, Rinse K, Knight, Robert, Guarner, Francisco, Shanahan, Fergus, Cani, Patrice D, Elinav, Eran, Sanguinetti, Maurizio, de Vos, Willem M, El-Omar, Emad, Dorè, Joel, Marchesi, Julian, Tilg, Herbert, Sokol, Harry, Segata, Nicola, Cammarota, Giovanni, Gasbarrini, Antonio, and Ianiro, Gianluca

Published
2025
Full Text
View/download PDF

2. Faecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): a randomised, double-blinded, placebo-controlled trial

Author

Høyer, Katrine Lundby, Dahl Baunwall, Simon Mark, Kornum, Ditte Smed, Klinge, Mette Winther, Drewes, Asbjørn Mohr, Yderstræde, Knud Bonnet, Thingholm, Louise Bruun, Mortensen, Martin Steen, Mikkelsen, Susan, Erikstrup, Christian, Hvas, Christian Lodberg, and Krogh, Klaus

Published
2025
Full Text
View/download PDF

4. Early geriatric assessment and management in older patients with Clostridioides difficile infection in Denmark (CLODIfrail): a randomised trial

Author

Rubak, Tone, Baunwall, Simon Mark Dahl, Gregersen, Merete, Paaske, Sara Ellegaard, Asferg, Malene, Barat, Ishay, Secher-Johnsen, Joanna, Riis, Mikael Groth, Rosenbæk, Jeppe Bakkestrøm, Hansen, Troels Kjærskov, Ørum, Marianne, Steves, Claire J, Veilbæk, Hanne, Hvas, Christian Lodberg, and Damsgaard, Else Marie Skjøde

Published
2024
Full Text
View/download PDF

10. Real-world Effectiveness of Fecal Microbiota Transplantation for First or Second Clostridioides difficile Infection

Author

Paaske, Sara Ellegaard, Baumwall, Simon Mark Dahl, Rubak, Tone, Birn, Frederik Hyllested, Rågård, Nina, Kelsen, Jens, Hansen, Mette Mejlby, Svenningsen, Lise, Krarup, Anne Lund, Fernis, Christa Marie Culmbach, Neumann, Anders, Lødrup, Anders Bergh, Glerup, Henning, Vinter-Jensen, Lars, Helms, Morten, Erikstrup, Lise Tornvig, Grosen, Anne Karmisholt, Mikkelsen, Susan, Erikstrup, Christian, Dahlerup, Jens Frederik, and Hvas, Christian Lodberg

Published
2024
Full Text
View/download PDF

13. ESPEN guideline on Clinical Nutrition in inflammatory bowel disease

Author

Bischoff, Stephan C., Bager, Palle, Escher, Johanna, Forbes, Alastair, Hébuterne, Xavier, Hvas, Christian Lodberg, Joly, Francisca, Klek, Stansilaw, Krznaric, Zeljko, Ockenga, Johann, Schneider, Stéphane, Shamir, Raanan, Stardelova, Kalina, Bender, Darija Vranesic, Wierdsma, Nicolette, and Weimann, Arved

Published
2023
Full Text
View/download PDF

14. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial

Author

Baunwall, Simon Mark Dahl, Andreasen, Sara Ellegaard, Hansen, Mette Mejlby, Kelsen, Jens, Høyer, Katrine Lundby, Rågård, Nina, Eriksen, Lotte Lindgreen, Støy, Sidsel, Rubak, Tone, Damsgaard, Else Marie Skjøde, Mikkelsen, Susan, Erikstrup, Christian, Dahlerup, Jens Frederik, and Hvas, Christian Lodberg

Published
2022
Full Text
View/download PDF

15. Metabolic stress in patients with acute severe ulcerative colitis - a single-center cohort study.

Author

Redsted, Mathias, Grønhøj, Magnus, Brøchner, Louise Dalsgaard, Fassov, Janne, Svart, Mads Vandsted, Andersen, Jens Rikardt, and Hvas, Christian Lodberg

Subjects
INSULIN resistance, ULCERATIVE colitis, BASAL metabolism, BIOELECTRIC impedance, BLOOD sugar
Abstract

Background and aims: Acute severe ulcerative colitis (ASUC) is characterized by systemic inflammation, which may initiate an acute-phase response leading to hypercatabolism. Patients with ASUC are usually treated with high-dose steroids that may further accelerate the metabolic response and lead to hyperglycemia and insulin resistance. Nevertheless, the degree of synergy between inflammation and steroid treatment and their influence on the insulin resistance remains unknown. We aimed to measure the degree of metabolic stress including insulin resistance in patients with ASUC during admission and three weeks after discharge. Methods: This single-center cohort study was conducted in adult patients with ASUC, defined and assessed by Truelove and Witt's criteria. Indirect calorimetry, bioelectrical impedance analysis, and the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) were applied at baseline and at follow-up three weeks after discharge. Results: Among the 22 patients admitted during the project period, 15 provided consent for participation in the study. Median C-reactive protein at inclusion was 37.6 [4; 154.7]. Both median HOMA-IR and fasting plasma glucose were markedly increased at inclusion (median 8.6 [3.8; 14.1] and 7.1 [6; 8.7], respectively), and both had decreased significantly three weeks after discharge (p=0.0036 and p=0.0039, respectively). No significant differences were observed in resting energy expenditure or anthropometric measurements from baseline to follow-up. Conclusion: Patients with ASUC presented with marked insulin resistance, indicating that the days following admission and high-dose steroid treatment are particularly vulnerable. Despite improvement at three-week follow-up, patients still exhibited insulin resistance compared with relevant control groups. Clinical trial registration: ClinicalTrials.gov, identifier NCT0527183. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Impact of gluten intake on clinical outcomes in patients with chronic inflammatory diseases initiating biologics: Secondary analysis of the prospective multicentre BELIEVE cohort study.

Author

Gregersen, Laura, Jessen, Pernille Dyhre, Lund, Helene Wiencke, Overgaard, Silja Hvid, Hikmat, Zainab, Ellingsen, Torkell, Kjeldsen, Jens, Pedersen, Andreas Kristian, Petersen, Sofie Ronja, Jawhara, Mohamad, Nexøe, Anders Bathum, Bygum, Anette, Hvas, Christian Lodberg, Dahlerup, Jens Frederik, Bergenheim, Frederik Olof, Glerup, Henning, Henriksen, Rikke Holm, Guldmann, Tanja, Hvid, Lone, and Brodersen, Jacob

Subjects
CROHN'S disease, ULCERATIVE colitis, PSORIATIC arthritis, GLUTEN, CHRONICALLY ill
Abstract

Chronic inflammatory diseases (CIDs) pose a growing healthcare challenge, with a substantial proportion of patients showing inadequate response to biological treatment. There is renewed interest in dietary changes to optimize treatment regimens, with a growing body of evidence suggesting beneficial effects with adherence to a gluten‐free diet. This study compared the likelihood of achieving clinical response to biological treatment after 14–16 weeks in patients with CID with high versus low‐to‐medium gluten intake. Secondary outcomes of interest included changes in disease activity, health‐related quality of life and C‐reactive protein. The study was a multicentre prospective cohort of 193 participants with a CID diagnosis (i.e. Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis or Psoriasis) who initiated biological treatment between 2017 and 2020. Participants were stratified based on their habitual gluten intake: the upper 33.3% (high gluten intake) and the remaining 66.6% (low‐to‐medium gluten intake). The proportion of patients achieving clinical response to biological treatment after 14–16 weeks was compared using logistic regression models. The median gluten intake differed significantly between groups (12.5 g/day vs. 5.9 g/day, standardized mean difference = 1.399). In total, 108 (56%) achieved clinical response to treatment, with no difference between 35 (55%) in the high gluten group and 73 (57%) in the medium‐to‐low gluten group (OR = 0.96 [0.51–1.79], p = 0.897). No differences were found with secondary outcomes. In conclusion, this study found no association between gluten intake and response to biological treatment in patients with CID. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey

Author

Baunwall, Simon Mark Dahl, Terveer, Elisabeth M, Dahlerup, Jens Frederik, Erikstrup, Christian, Arkkila, Perttu, Vehreschild, Maria JGT, Ianiro, Gianluca, Gasbarrini, Antonio, Sokol, Harry, Kump, Patrizia K, Satokari, Reetta, De Looze, Danny, Vermeire, Séverine, Nakov, Radislav, Brezina, Jan, Helms, Morten, Kjeldsen, Jens, Rode, Anne A, Kousgaard, Sabrina Just, Alric, Laurent, Trang-Poisson, Caroline, Scanzi, Julien, Link, Alexander, Stallmach, Andreas, Kupcinskas, Juozas, Johnsen, Peter Holger, Garborg, Kjetil, Rodríguez, Eugenia Sánchez, Serrander, Lena, Brummer, Robert J, Galpérine, Katerina Tatiana, Goldenberg, Simon D, Mullish, Benjamin H, Williams, Horace RT, Iqbal, Tariq H, Ponsioen, Cyriel, Kuijper, Ed J, Cammarota, Giovanni, Keller, Josbert J, and Hvas, Christian Lodberg

Published
2021
Full Text
View/download PDF

19. Effects of smoking on clinical treatment outcomes amongst patients with chronic inflammatory diseases initiating biologics: secondary analyses of the prospective BELIEVE cohort study.

Author

Larsen, Maja Graves Rosenkilde, Overgaard, Silja Hvid, Petersen, Sofie Ronja, Møllegaard, Karen Mai, Munk, Heidi Lausten, Nexøe, Anders Bathum, Glerup, Henning, Guldmann, Tanja, Pedersen, Natalia, Saboori, Sanaz, Dahlerup, Jens Frederik, Hvas, Christian Lodberg, Andersen, Karina Winther, Jawhara, Mohamad, Haagen Nielsen, Ole, Bergenheim, Fredrik Olof, Brodersen, Jacob Broder, Bygum, Anette, Ellingsen, Torkell, and Kjeldsen, Jens

Subjects
CROHN'S disease, BIOTHERAPY, ULCERATIVE colitis, RHEUMATOID arthritis, CHRONICALLY ill
Abstract

The prevalence and disease burden of chronic inflammatory diseases (CIDs) are predicted to rise. Patients are commonly treated with biological agents, but the individual treatment responses vary, warranting further research into optimizing treatment strategies. This study aimed to compare the clinical treatment responses in patients with CIDs initiating biologic therapy based on smoking status, a notorious risk factor in CIDs. In this multicentre cohort study including 233 patients with a diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis or psoriasis initiating biologic therapy, we compared treatment response rates after 14 to 16 weeks and secondary outcomes between smokers and non‐smokers. We evaluated the contrast between groups using logistic regression models: (i) a "crude" model, only adjusted for the CID type, and (ii) an adjusted model (including sex and age). Among the 205 patients eligible for this study, 53 (26%) were smokers. The treatment response rate among smokers (n = 23 [43%]) was lower compared to the non‐smoking CID population (n = 92 [61%]), corresponding to a "crude" OR of 0.51 (95% CI: [0.26;1.01]) while adjusting for sex and age resulted in consistent findings: 0.51 [0.26;1.02]. The contrast was apparently most prominent among the 38 RA patients, with significantly lower treatment response rates for smokers in both the "crude" and adjusted models (adjusted OR 0.13, [0.02;0.81]). Despite a significant risk of residual confounding, patients with CIDs (rheumatoid arthritis in particular) should be informed that smoking probably lowers the odds of responding sufficiently to biological therapy. Registration: Clinical.Trials.gov NCT03173144. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Opium tincture has anti-propulsive effects in patients with chronic diarrhea: a randomized, placebo-controlled, and cross-over trial.

Author

Okdahl, Tina, Høyer, Katrine Lundby, Knoph, Cecilie Siggaard, Davidsen, Line, Larsen, Isabelle Myriam, Mark, Esben Bolvig, Hvas, Christian Lodberg, Krogh, Klaus, and Drewes, Asbjørn Mohr

Subjects
GASTROINTESTINAL motility, CROSSOVER trials, CENTRAL nervous system, QUALITY of life, OPIUM, ADDICTIONS
Abstract

Objective: Chronic diarrhea affects approximately 5% of the population. Opioids inhibit gastrointestinal motility, and opium tincture has shown anti-propulsive effects in healthy, but no controlled studies of its clinical efficacy exist. We aimed to investigate the anti-propulsive and central nervous system (CNS) effects of opium tincture in patients with chronic diarrhea. Materials and methods: The study was a randomized, double-blinded, placebo-controlled, cross-over trial in subjects with chronic diarrhea refractory to standard treatment. Participants received opium tincture or placebo during two intervention periods, each lasting seven days. Bowel movements were recorded daily, and gastrointestinal transit time was investigated with the wireless motility capsule system. Gastrointestinal symptoms, health-related quality of life, and CNS effects (pupil size, reaction time, memory, and general cognition) were also investigated, along with signs of addiction. Results: Eleven subjects (mean age: 45 ± 17 years, 46% males) with a median of 4.7 daily bowel movements were included. The number of daily bowel movements was reduced during opium tincture treatment to 2.3 (p = 0.045), but not placebo (3.0, p = 0.09). Opium tincture prolonged the colonic transit time compared to placebo (17 h vs. 12 h, p < 0.001). In both treatment arms, there were no changes in self-reported gastrointestinal symptoms, health-related quality of life, or CNS effects, and no indication of addiction was present. Conclusion: Opium tincture induced anti-propulsive effects in patients with chronic diarrhea refractory to standard treatment. This indicates that opium tincture is a relevant treatment strategy for selected patients with chronic diarrhea. Moreover, no evidence of opioid-induced sedation or addiction was found. Trial Registration Number: NCT05690321 (registered 2023-01-10) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Editorial: Continuous monitoring to improve outcome of treatment—the next step towards safe and effective faecal microbiota transplantation. Authors' reply

Author

Baunwall, Simon Mark Dahl, primary, Hansen, Mette Mejlby, additional, Andreasen, Sara Ellegaard, additional, Eriksen, Marcel Kjærsgaard, additional, Rågård, Nina, additional, Kelsen, Jens, additional, Grosen, Anne Karmisholt, additional, Mikkelsen, Susan, additional, Erikstrup, Christian, additional, Dahlerup, Jens Frederik, additional, and Hvas, Christian Lodberg, additional

Published
2023
Full Text
View/download PDF

30. Tarmen

Author

HVAS, CHRISTIAN LODBERG and HVAS, CHRISTIAN LODBERG

Published
2021

31. Sodium depletion and secondary hyperaldosteronism in outpatients with an ileostomy: a cross-sectional study

Author

Rud, Charlotte Lock, Brantlov, Steven, Quist, Josephine Reinert, Wilkens, Trine Levring, Dahlerup, Jens Frederik, Lal, Simon, Jeppesen, Palle Bekker, Hvas, Christian Lodberg, Rud, Charlotte Lock, Brantlov, Steven, Quist, Josephine Reinert, Wilkens, Trine Levring, Dahlerup, Jens Frederik, Lal, Simon, Jeppesen, Palle Bekker, and Hvas, Christian Lodberg

Abstract

Objective: Patients with an ileostomy may experience postoperative electrolyte derangement and dehydration but are presumed to stabilise thereafter. We aimed to investigate the prevalence of sodium depletion in stable outpatients with an ileostomy and applied established methods to estimate their fluid status. Methods: We invited 178 patients with an ileostomy through a region-wide Quality-of-Life-survey to undergo outpatient evaluation of their sodium and fluid status. The patients delivered urine and blood samples, had bioelectrical impedance analysis performed and answered a questionnaire regarding dietary habits. Results: Out of 178 invitees, 49 patients with an ileostomy were included; 22 patients (45%, 95% CI, 31–59%) had unmeasurably low urinary sodium excretion (<20 mmol/L), indicative of chronic sodium depletion, and 26% (95% CI, 16–41%) had plasma aldosterone levels above the reference value. Patients with unmeasurably low urinary sodium excretion had low estimated glomerular filtration rates (median 76, IQR 63–89, mL/min/1.73m2) and low venous blood plasma CO2 (median 24, IQR 21–26, mmol/L), indicative of chronic renal impairment and metabolic acidosis. Bioelectrical impedance analysis, plasma osmolality, creatinine and sodium values were not informative in determining sodium status in this population. Conclusion: A high proportion of patients with an ileostomy may be chronically sodium depleted, indicated by absent urinary sodium excretion, secondary hyperaldosteronism and chronic renal impairment, despite normal standard biochemical tests. Sodium depletion may adversely affect longstanding renal function. Future studies should investigate methods to estimate and monitor fluid status and aim to develop treatments to improve sodium depletion and dehydration in patients with an ileostomy.

Published
2023

33. Clostridioides difficile infection in frail older patients, quality in treatment and care: the CLODIFRAIL study protocol for a multicentre randomised controlled trial

Author

Rubak, Tone, primary, Veilbæk, Hanne, additional, Gregersen, Merete, additional, Asferg, Malene, additional, Barat, Ishay, additional, Johnsen, Joanna Secher, additional, Riis, Mikael Groth, additional, Rosenbæk, Jeppe, additional, Ørum, Marianne, additional, Vinding, Rita Stockholm, additional, Sørensen, Carl Aksel Kragh, additional, Steves, Claire J, additional, Baunwall, Simon Mark Dahl, additional, Hvas, Christian Lodberg, additional, and Damsgaard, Else Marie Skjøde, additional

Published
2023
Full Text
View/download PDF

34. Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection – Authors' reply

Author

Baunwall, Simon Mark Dahl, primary, Andreasen, Sara Ellegaard, additional, Hansen, Mette Mejlby, additional, Kelsen, Jens, additional, Høyer, Katrine Lundby, additional, Rågård, Nina, additional, Eriksen, Lotte Lindgreen, additional, Støy, Sidsel, additional, Rubak, Tone, additional, Damsgaard, Else Marie Skjøde, additional, Mikkelsen, Susan, additional, Erikstrup, Christian, additional, Dahlerup, Jens Frederik, additional, and Hvas, Christian Lodberg, additional

Published
2023
Full Text
View/download PDF

36. Real-World Effectiveness of Faecal Microbiota Transplantation (FMT) for First or Second Clostridioides Difficile Infection (CDI): A Cohort Study

Author

Andreasen, Sara Ellegaard, primary, Baumwall, Simon Mark Dahl, additional, Rubak, Tone, additional, Birn, Frederik Hyllested, additional, Rågård, Nina, additional, Kelsen, Jens, additional, Hansen, Mette Mejlby, additional, Svenningsen, Lise, additional, Krarup, Anne Lund, additional, Fernis, Christa Marie Culmbach, additional, Neumann, Anders, additional, Lødrup, Anders Bergh, additional, Glerup, Henning, additional, Vinter-Jensen, Lars, additional, Helms, Morten, additional, Erikstrup, Lise Tornvig, additional, Grosen, Anne Karmisholt, additional, Mikkelsen, Susan, additional, Erikstrup, Christian, additional, Dahlerup, Jens Frederik, additional, and Hvas, Christian Lodberg, additional

Published
2023
Full Text
View/download PDF

41. Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection

Author

Wei, Shaodong, Bahl, Martin Iain, Baunwall, Simon Mark Dahl, Dahlerup, Jens Frederik, Hvas, Christian Lodberg, Licht, Tine Rask, Wei, Shaodong, Bahl, Martin Iain, Baunwall, Simon Mark Dahl, Dahlerup, Jens Frederik, Hvas, Christian Lodberg, and Licht, Tine Rask

Abstract

In fecal microbiota transplantation (FMT) against recurrent Clostridioides difficile infection (CDI), clinical outcomes are usually determined after 8 weeks. We hypothesized that the intestinal microbiota changes earlier than this timepoint, and analyzed fecal samples obtained 1 week after treatment from 64 patients diagnosed with recurrent CDI and included in a randomized clinical trial, where the infection was treated with either vancomycin-preceded FMT (N = 24), vancomycin (N = 16) or fidaxomicin (N = 24). In comparison with non-responders, patients with sustained resolution after FMT had increased microbial alpha diversity, enrichment of Ruminococcaceae and Lachnospiraceae, depletion of Enterobacteriaceae, more pronounced donor microbiota engraftment, and resolution of gut microbiota dysbiosis. We found that a constructed index, based on markers for the identified genera Escherichia and Blautia, successfully predicted clinical outcomes at Week 8, which exemplifies a way to utilize clinically feasible methods to predict treatment failure. Microbiota changes were restricted to patients who received FMT rather than antibiotic monotherapy, indicating that FMT confers treatment response in a different way than antibiotics. We suggest that early identification of microbial community structures after FMT is of clinical value to predict response to the treatment.

Published
2022

42. Cross-generational bacterial strain transfer to an infant after fecal microbiota transplantation to a pregnant patient:a case report

Author

Wei, Shaodong, Jespersen, Marie Louise, Baunwall, Simon Mark Dahl, Myers, Pernille Neve, Smith, Emilie Milton, Dahlerup, Jens Frederik, Rasmussen, Simon, Nielsen, Henrik Bjørn, Licht, Tine Rask, Bahl, Martin Iain, Hvas, Christian Lodberg, Wei, Shaodong, Jespersen, Marie Louise, Baunwall, Simon Mark Dahl, Myers, Pernille Neve, Smith, Emilie Milton, Dahlerup, Jens Frederik, Rasmussen, Simon, Nielsen, Henrik Bjørn, Licht, Tine Rask, Bahl, Martin Iain, and Hvas, Christian Lodberg

Abstract

Background: Fecal microbiota transplantation (FMT) effectively prevents the recurrence of Clostridioides difficile infection (CDI). Long-term engraftment of donor-specific microbial consortia may occur in the recipient, but potential further transfer to other sites, including the vertical transmission of donor-specific strains to future generations, has not been investigated. Here, we report, for the first time, the cross-generational transmission of specific bacterial strains from an FMT donor to a pregnant patient with CDI and further to her child, born at term, 26 weeks after the FMT treatment. Methods: A pregnant woman (gestation week 12 + 5) with CDI was treated with FMT via colonoscopy. She gave vaginal birth at term to a healthy baby. Fecal samples were collected from the feces donor, the mother (before FMT, and 1, 8, 15, 22, 26, and 50 weeks after FMT), and the infant (meconium at birth and 3 and 6 months after birth). Fecal samples were profiled by deep metagenomic sequencing for strain-level analysis. The microbial transfer was monitored using single nucleotide variants in metagenomes and further compared to a collection of metagenomic samples from 651 healthy infants and 58 healthy adults. Results: The single FMT procedure led to an uneventful and sustained clinical resolution in the patient, who experienced no further CDI-related symptoms up to 50 weeks after treatment. The gut microbiota of the patient with CDI differed considerably from the healthy donor and was characterized as low in alpha diversity and enriched for several potential pathogens. The FMT successfully normalized the patient’s gut microbiota, likely by donor microbiota transfer and engraftment. Importantly, our analysis revealed that some specific strains were transferred from the donor to the patient and then further to the infant, thus demonstrating cross-generational microbial transfer. Conclusions: The evidence for cross-generational strain transfer following FMT provides novel in

Published
2022

43. Patient-reported outcomes and health-related quality of life in people living with ileostomies: A population-based, cross-sectional study

Author

Rud, Charlotte L, Baunwall, Simon Mark Dahl, Bager, Palle, Dahlerup, Jens Frederik, Wilkens, Trine L, Tøttrup, Anders, Lal, Simon, Hvas, Christian Lodberg, Rud, Charlotte L, Baunwall, Simon Mark Dahl, Bager, Palle, Dahlerup, Jens Frederik, Wilkens, Trine L, Tøttrup, Anders, Lal, Simon, and Hvas, Christian Lodberg

Abstract

Background: The impact of a stoma on long-term health-related quality of life in people living with ileostomies is not clear. Objective: This study aimed to describe important patient-reported outcomes and health-related quality of life in people with ileostomies. Design: This is a population-based, cross-sectional study. Patients were invited to answer questionnaires estimating stoma-specific and generic health-related quality of life (EQ-5D-5L and the Major Depression Inventory). Danish norms were retrieved from reference literature. Settings: This study was conducted at the major stoma clinic at Aarhus University Hospital, Denmark. Patients: We invited all patients with ileostomies who were in contact with the clinic between 2012 and 2017. Main outcome measures: The primary outcomes measured were patient-reported outcomes specific to people with ileostomies. Results: Of 621 identified patients (50% women), 412 (67%) responded to the survey. Among the responders, 178 (43%) reported that they still had an ileostomy at the time of the survey and were included in the analysis. Fatigue was frequent; 68% (95% CI 60%-75%) reported being tired and 26% (95% CI 20%-33%) answered that they were "always tired," whereas 43% (95% CI 36%-51%) lacked energy, 62% (95% CI 54%-69%) reported poor sleep, and 59% (95% CI 52%-66%) needed to rest during the day. Fifty-six percent (95% CI 48%-63%) needed to know the immediate location of the nearest toilet, and 58% (95% CI 51%-66%) felt sexually unattractive because of their ileostomy. Health-related quality of life measured with generic questions indicated 0.124 points lower health-related quality of life than the Danish norm (p < 0.001), and 18% (95% CI 13%-25%) scored above the threshold for depression, which is 2.6 times higher than the background population (7%, 95% CI 6%-9%; p < 0.001). Limitations: This study was limit

Published
2022

45. Additional file 2 of Cross-generational bacterial strain transfer to an infant after fecal microbiota transplantation to a pregnant patient: a case report

Author

Wei, Shaodong, Jespersen, Marie Louise, Baunwall, Simon Mark Dahl, Myers, Pernille Neve, Smith, Emilie Milton, Dahlerup, Jens Frederik, Rasmussen, Simon, Nielsen, Henrik Bjørn, Licht, Tine Rask, Bahl, Martin Iain, and Hvas, Christian Lodberg

Abstract

Additional file 2: Section S1. Additional details for strain transfer findings.

Published
2022
Full Text
View/download PDF

46. Additional file 1 of Cross-generational bacterial strain transfer to an infant after fecal microbiota transplantation to a pregnant patient: a case report

Author

Wei, Shaodong, Jespersen, Marie Louise, Baunwall, Simon Mark Dahl, Myers, Pernille Neve, Smith, Emilie Milton, Dahlerup, Jens Frederik, Rasmussen, Simon, Nielsen, Henrik Bjørn, Licht, Tine Rask, Bahl, Martin Iain, and Hvas, Christian Lodberg

Abstract

Additional file 1: Fig. S1. Medical history for the patient from onset of CDI symptoms to FMT treatment and delivery of an infant. Fig. S2. The estimated genome coverage based on the Nonpareil. Fig. S3. Illustrations of the strain detection methods. Fig. S4. Detection of the C. difficile toxin producing genes with qPCR. Fig. S5. Tree plots to show the differences in the taxa relative abundances at different taxonomic levels. Fig. S6. Beta diversity of donors and patient post-FMT. Fig. S7. Short-chain fatty acids detected in the fecal samples. Fig. S8. Heatmap to show the top 50 species having the largest variance across donor and patient samples. Fig. S9. A diagram to show the division of the gut microbiota in the patient post-FMT. Fig. S10. Proportion of transferred donor-specific species. Fig. S11. Bray-Curtis distance to show the dissimilarity between the patient post-FMT and the patient pre-FMT. Fig. S12. The relative abundances of species in the patient post-FMT when divided into different potential sources. Fig. S13. Heatmap to show the donor-specific species in the patient gut after FMT. Fig. S14. Benchmarking of discriminative positions method and percentage of identical alleles method. Fig. S15. Detected donor strains in patient and infant samples across 120 different species based on the percentage of identical alleles between strains identified in the donor and in the patient or infant samples. Fig. S16. Detection of donor strain in the 14 species with one or more samples with another strain detected. Fig. S17. Changes in the number of species detected to have strain transfer from the donor.

Published
2022
Full Text
View/download PDF

49. Faecal Microbiota Transplantation Eradicated Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae from a Renal Transplant Recipient with Recurrent Urinary Tract Infections

Author

Grosen, Anne Karmisholt, Povlsen, Johan Vestergaard, Lemming, Lars Erik, Jørgensen, Simon Mark Dahl, Dahlerup, Jens Frederik, and Hvas, Christian Lodberg

Subjects
Faecal microbiota transplantation, Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Multidrug-resistant microorganisms, Case Report, Renal transplantation, bacterial infections and mycoses, Intestinal decolonisation
Abstract

Renal transplant recipients (RTRs) are highly susceptible to infections, and antimicrobial resistance is an increasing problem with limited treatment options. Faecal microbiota transplantation (FMT) is effective for recurrent Clostridium difficile infection and may be used for patients with intestinal carriage of multidrug-resistant (MDR) microorganisms. We present a RTR who suffered from recurrent urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase-producing (ESBL+) Klebsiella pneumoniae. Blood and urinary isolates revealed the same antibiotic susceptibility pattern, and whole-genome sequencing confirmed identical isolates in blood and urine. Despite several treatments with meropenem, the patient experienced recurrent infections that caused hospitalisation. ESBL+ K. pneumoniae was isolated in faeces. In an attempt to decolonise the gut, FMT was performed. A few days after nasojejunal infusion of donor faeces, the patient experienced a single relapse of UTI. During the subsequent 12 months, no further episodes of UTI occurred. Absence of ESBL+ K. pneumoniae in urine and faeces was demonstrated during follow-up. We conclude that FMT may be an effective treatment in RTRs with recurrent UTIs caused by intestinal colonisation with MDR organisms.

Published
2019
Full Text
View/download PDF

50. SARS-CoV-2 vaccines and donor recruitment for FMT

Author

Ianiro, Gianluca, Mullish, Benjamin H, Hvas, Christian Lodberg, Segal, Jonathan P, Kuijper, Ed J, Costello, Samuel P, Kelly, Colleen R, Allegretti, Jessica R, Fischer, Monika, Iqbal, Tariq H, Satokari, Reetta, Kao, Dina, van Prehn, Joffrey, Ng, Siew C, Bibbò, Stefano, Baunwall, Simon Mark Dahl, Quraishi, Mohammed N, Sokol, Harry, Zhang, Faming, Keller, Josbert, Masucci, Luca, Quaranta, Gianluca, Kassam, Zain, Sanguinetti, Maurizio, Tilg, Herbert, Gasbarrini, Antonio, and Cammarota, Giovanni

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results